The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).
Emmanuel S. Antonarakis
Consultant or Advisory Role - Dendreon; Dendreon; Dendreon
Research Funding - Dendreon; Dendreon; Dendreon
Adam Kibel
Consultant or Advisory Role - Dendreon
Robert Claude Tyler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Candice McCoy
Employment or Leadership Position - Dendreon; Dendreon
Stock Ownership - Dendreon; Dendreon
Yang Wang
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Charles G. Drake
Consultant or Advisory Role - Amplimmune; Bristol-Myers Squibb; Dendreon